Library · Immune · Treatment of non-metastatic osteosarcoma
Mifamurtide
L-MTP-PE, Liposomal muramyl tripeptide phosphatidylethanolamine, CGP 19835
A synthetic analogue of muramyl dipeptide, a bacterial cell-wall fragment, that stimulates immune cells. Approved in Europe (Mepact) alongside chemotherapy after surgery for high-grade, non-metastatic osteosarcoma to lower recurrence risk.
Research score 85/100. Reference only, not a dose.
- Immune Boosting
- Anti-cancer
- Anti-inflammatory
- Inflammation Resolution
- US status
- FDA Approved
- Approval
- EMA Approved
- Evidence
- Approved in Europe/Israel (Mepact). Not FDA approved.
- Research score
- 85 / 100
- Indication
- Multiple Approved Indications
- Origin
- USA
- Source category
- Immune System
- Status group
- Approved / prescription
Mechanism
Binds NOD2 on monocytes and macrophages, raising TNF-α, IL-1β, IL-6, and IL-12 output and boosting macrophage and dendritic-cell activity against tumor cells, including recruitment of immune cells to the tumor site.
Safety file
Flu-like symptoms such as fever, chills, and fatigue are frequent; GI upset occurs; severe allergic reactions are rare.
- Fever
- Chills
- Fatigue
- Headache
- Nausea
- Tachycardia
- Hypotension
- Muscle pain